Boost and loss of immune responses against tumor-associated antigens in the course of pregnancy as a model for allogeneic immunotherapy

Blood

Volumn 125, Issue 2, 2015, Pages 261-272

  Lutz, Mathias ^a   Worschech, Andrea ^a,b   Alb, Miriam ^a   Gahn, Sabine ^a   Bernhard, Laura ^a   Schwab, Michael ^a   Obermeier, Stefanie ^a   Einsele, Hermann ^a   Kämmerer, Ulrike ^a   Heuschmann, Peter ^a   Klinker, Erdwine ^a   Otto, Christoph ^a   Mielke, Stephan ^a  

^a Würzburg University Medical Center   (Germany)

^b WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER TESTIS ANTIGEN; GAMMA INTERFERON; MUCIN 1; PEPTIDE; TUMOR ANTIGEN; HLA A2 ANTIGEN;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; BLOOD DONOR; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; FEMALE; GONAD; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; MALE; MIDDLE AGED; PREGNANCY; PRIMARY IMMUNE RESPONSE; PRIMIGRAVIDA; PRIORITY JOURNAL; VACCINATION; CROSS-SECTIONAL STUDY; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; YOUNG ADULT;

ADULT; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; FEMALE; GRAFT VS HOST DISEASE; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PREGNANCY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84920971354     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-601302     Document Type: Article

References (68)

1. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300(19):1068-1073.
2. Sullivan KM, Storb R, Buckner CD, et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med. 1989;320(13):828-834.
3. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3):555-562.
4. Loren AW, Bunin GR, Boudreau C, et al. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(7):758-769.
5. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood. 1999;93(7):2336-2341.
6. Feng X, Hui KM, Younes HM, Brickner AG. Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses. Trends Immunol. 2008;29(12): 624-632.
7. Falkenburg JH, Marijt WA, Heemskerk MH, Willemze R. Minor histocompatibility antigens as targets of graft-versus-leukemia reactions. Curr Opin Hematol. 2002;9(6):497-502.
8. Falkenburg JH, Willemze R. Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia. Best Pract Res Clin Haematol. 2004;17(3):415-425.
9. Nonn M, Herr W, Khan S, et al. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering. Transplantation. 2008; 86(10):1427-1435.
10. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6(9):1018-1023.
11. Rezvani K, Barrett AJ. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract Res Clin Haematol. 2008;21(3): 437-453.
12. Rezvani K, Grube M, Brenchley JM, et al. Functional leukemia-associated antigen-specific memory CD81 T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood. 2003;102(8):2892-2900.
13. Molldrem JJ, Komanduri K, Wieder E. Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions. Curr Opin Hematol. 2002;9(6):503-508.
14. Morris EC, Bendle GM, Stauss HJ. Prospects for immunotherapy of malignant disease. Clin Exp Immunol. 2003;131(1):1-7.
15. Natzke AM, Shaw JL, McKeller MR, Emo KL, Mullen CA. Hematopoietic stem cell recipients do not develop post-transplantation immune tolerance to antigens present on minimal residual disease. Biol Blood Marrow Transplant. 2007; 13(1):34-45.
16. Wrzesinski C, Paulos CM, Gattinoni L, et al. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest. 2007;117(2):492-501.
17. Piper KP, McLarnon A, Arrazi J, et al. Functional HY-specific CD81 T cells are found in a high proportion of women following pregnancy with a male fetus. Biol Reprod. 2007;76(1):96-101.
18. Verdijk RM, Kloosterman A, Pool J, et al. Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy. Blood. 2004;103(5):1961-1964.
19. Takami A, Sugimori C, Feng X, et al. Expansion and activation of minor histocompatibility antigen HY-specific T cells associated with graft-versusleukemia response. Bone Marrow Transplant. 2004;34(8):703-709.
20. Nakamura R, La Rosa C, Tsai W, et al. Ex vivo detection of CD8 T cells specific for H-Y minor histocompatibility antigens in allogeneic hematopoietic stem cell transplant recipients. Transpl Immunol. 2014;30(4):128-135.
21. Meden H, Mielke S, Schauer A, Kuhn W. Serum levels of the c-erbB-2 (HER2/neu) encoded oncoprotein fragment p105 in normal pregnancies. In Vivo. 1997;11(1):51-54.
22. Jeschke U, Richter DU, Hammer A, Briese V, Friese K, Karsten U. Expression of the Thomsen-Friedenreich antigen and of its putative carrier protein mucin 1 in the human placenta and in trophoblast cells in vitro. Histochem Cell Biol. 2002;117(3):219-226.
23. Ikeda H, Lethé B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6(2):199-208.
24. Feingold M, Zilberstein M, Srivastava RK, Seibel MM, Bar-Ami S, Hambartsoumian E. Expression of Wilms' tumor suppressor gene (WT1) in term human trophoblast: regulation by cyclic adenosine 39, 5 9-monophosphate. J Clin Endocrinol Metab. 1998;83(7):2503-2508.
25. Dietz AB, Bulur PA, Emery RL, et al. A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. Transfusion. 2006;46(12):2083-2089.
26. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med. 1995;181(6):2109-2117.
27. Brossart P, Schneider A, Dill P, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 2001;61(18):6846-6850.
28. Rezvani K, Yong AS, Tawab A, et al. Ex vivo characterization of polyclonal memory CD81 T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood. 2009; 113(10):2245-2255.
29. Salter RD, Howell DN, Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics. 1985; 21(3):235-246.
30. Britten CM, Meyer RG, Kreer T, Drexler I, Wölfel T, Herr W. The use of HLA-A∗0201-transfected K562 as standard antigenpresenting cells for CD8(1) T lymphocytes in IFN-gamma ELISPOT assays. J Immunol Methods. 2002;259(1-2):95-110.
31. Römer PS, Berr S, Avota E, et al. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood. 2011; 118(26):6772-6782.
32. Bleakley M, Turtle CJ, Riddell SR. Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol. 2012;5(4): 409-425.
33. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22): 2091-2101.
34. Warren EH, Deeg HJ. Dissecting graft-versusleukemia from graft-versus-host-disease using novel strategies. Tissue Antigens. 2013;81(4): 183-193.
35. Arora M. Therapy of chronic graft-versus-host disease. Best Pract Res Clin Haematol. 2008; 21(2):271-279.
36. Inamoto Y, Flowers ME, Lee SJ, et al. Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood. 2011;118(2):456-463.
37. Kotsiou E, Davies JK. New ways to separate graft-versus-host disease and graft-versustumour effects after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2013; 160(2):133-145.
38. Rezvani K, Yong AS, Savani BN, et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood. 2007;110(6): 1924-1932.
39. Fujiwara H. Adoptive T-cell therapy for hematological malignancies using T cells genemodified to express tumor antigen-specific receptors. Int J Hematol. 2014;99(2):123-131.
40. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112(12):4371-4383.
41. Rezvani K, Brenchley JM, Price DA, et al. T-cell responses directed against multiple HLA-A∗0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res. 2005; 11(24 Pt 1):8799-8807.
42. Weber G, Karbach J, Kuçi S, et al. WT1 peptidespecific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation. Leukemia. 2009;23(9): 1634-1642.
43. Scheibenbogen C, Letsch A, Thiel E, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood. 2002;100(6):2132-2137.
44. Agrawal B, Reddish MA, KrantzMJ, Longenecker BM. Does pregnancy immunize against breast cancer? Cancer Res. 1995;55(11):2257-2261.
45. Jungbluth AA, Silva WA Jr, Iversen K, et al. Expression of cancer-testis (CT) antigens in placenta. Cancer Immun. 2007;7:15.
46. Lahita RG. The effects of sex hormones on the immune system in pregnancy. Am J Reprod Immunol. 1992;28(3-4):136-137.
47. Jansson L, Holmdahl R. Estrogen-mediated immunosuppression in autoimmune diseases. Inflamm Res. 1998;47(7):290-301.
48. Valdimarsson H, Mulholland C, Fridriksdottir V, Coleman DV. A longitudinal study of leucocyte blood counts and lymphocyte responses in pregnancy: a marked early increase of monocytelymphocyte ratio. Clin Exp Immunol. 1983;53(2): 437-443.
49. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood. 1997;89(4):1405-1412.
50. Rezvani K, Yong AS, Mielke S, et al. Leukemiaassociated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111(1):236-242.
51. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996;183(3):725-729.
52. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004;4:1.
53. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5(8): 615-625.
54. Kohrt HE, Müller A, Baker J, et al. Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation. Blood. 2011;118(19): 5319-5329.
55. Bos R, Marquardt KL, Cheung J, Sherman LA. Functional differences between low- and highaffinity CD8(1) T cells in the tumor environment. OncoImmunology. 2012;1(8):1239-1247.
56. Dummer W, Niethammer AG, Baccala R, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest. 2002; 110(2):185-192.
57. Smyth K, Garcia K, Sun Z, Tuo W, Xiao Z. Repetitive peptide boosting progressively enhances functional memory CTLs. Biochem Biophys Res Commun. 2012;424(3):635-640.
58. Mielke S, McIver ZA, Shenoy A, et al. Selectively T cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies. Biol Blood Marrow Transplant. 2011;17(12):1855-1861.
59. Mielke S, Nunes R, Rezvani K, et al. A clinicalscale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood. 2008;111(8):4392-4402.
60. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 2014;27:1-7.
61. Hobeika AC, Morse MA, Osada T, Peplinski S, Lyerly HK, Clay TM. Depletion of human regulatory T cells. Methods Mol Biol. 2011;707: 219-231.
62. Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP31CD41 regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA. 2013;110(44):17945-17950.
63. Mielke S, Solomon SR, Barrett AJ. Selective depletion strategies in allogeneic stem cell transplantation. Cytotherapy. 2005;7(2):109-115.
64. Alsina M, Becker PS, Zhong X, et al Resource for Clinical Investigation in Blood and Marrow Transplantation. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(8):1183-1189.
65. Suzuki K, Aida K, Miyakawa R, et al. Preimmunization of donor lymphocytes enhances antitumor immunity of autologous hematopoietic stem cell transplantation. Cancer Med. 2013;2(5): 636-645.
66. Worschech A, Lutz M, Methner L, et al. Correlation of humoral and cellular Cytomegalovirus-specific immune responses in healthy donors: who is really negative or positive [abstract]? CIMT Annual Meeting Abstracts. 2011: 121.
67. Lutz M, Worschech A, Gahn S, et al. Immune responses against the tumor-associated antigens WT1, MUC-1, PRAME and HER2/neu in 114 prospectively screened healthy donors: Effects of gender and prior pregnancy and implications for immunotherapy [abstract]. Blood. 2012;120:4115.
68. Lutz M, Alb M, Worschech A, et al. Boost and loss of immune responses against tumor-associated antigens in the course of pregnancy as a model for immunotherapy [abstract]. Blood. 2013;122: 4505.